Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma
Preetesh Jain(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Francisco Vega(The University of Texas MD Anderson Cancer Center), David Santos(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Lucy Navsaria(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Cezar Iliescu(The University of Texas MD Anderson Cancer Center), Selvi Thirumurthi(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Yixin Yao(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Chi Young Ok(The University of Texas MD Anderson Cancer Center), Shuangtao Zhao(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Omar Moghrabi(The University of Texas MD Anderson Cancer Center), Lei Feng(Ministry of Public Security of the People's Republic of China), Michelle Avellaneda(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Holly A. Hill(National Center for Immunization and Respiratory Diseases), Yang Liu(The University of Texas MD Anderson Cancer Center), Guofan Xu(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Maria Badillo(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 82
Related Papers
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k